title: Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases.
abstract: OBJECTIVE
  Borderline ovarian tumors (BOTs) constitute about a quarter of epithelial ovarian malignancies and require different treatment approaches. The present study aims to document the experience of a single center on the treatment outcome of women who had conservative or comprehensive surgery for BOTs.
  
  
  METHODS
  One hundred eighty-three patients with BOTs, diagnosed and/or treated in our center between January of 2000 and March of 2013, were reviewed retrospectively.
  
  
  RESULTS
  The mean age at diagnosis was 40.6 years old (range 17-78). Ninety-five patients (51 %) were ≤40 years. Comprehensive surgical staging and fertility sparing surgery were performed in 49 % (n = 91) and 48 % of patients (n = 89) respectively. A hundred and forty-seven patients had stage IA disease (80 %). The most common type of BOT was serous in histology with 18 % bilateralism. CA-125 and CA-199 levels were increased in 29 (19 %) and 15 (10 %) patients with stage IA disease. Non-invasive tumor implants were diagnosed in 9 patients (4 %) and uterine involvement was 2 % among BOT patients that underwent hysterectomies. The mean post-operative follow-up period was 20.4 months (range 6-78 months). Disease recurrence was seen in 5 patients indicating overall recurrence rate of 2.7 %.
  
  
  CONCLUSIONS
  In our study, we evaluated a large data pool of 183 patients diagnosed with borderline epithelial ovarian tumors. BOTs have a relatively better prognosis than invasive epithelial ovarian cancer. Surgery with proper staging is the cornerstone of treatment. Patients with BOTs at the early stage can undergo fertility sparing surgery with close follow-up.
authors.affiliation: Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital, 06230, Hamamonu, Ankara, Turkey.
authors.forename: Tayfun
authors.initials: T
authors.lastname: Gungor
authors.forename: Nilufer
authors.initials: N
authors.lastname: Cetinkaya
authors.forename: Hakan
authors.initials: H
authors.lastname: Yalcin
authors.forename: Bulent
authors.initials: B
authors.lastname: Ozdal
authors.forename: Emre
authors.initials: E
authors.lastname: Ozgu
authors.forename: Eralp
authors.initials: E
authors.lastname: Baser
authors.forename: Dilek
authors.initials: D
authors.lastname: Uygur
authors.forename: Mete
authors.initials: M
authors.lastname: Caglar
authors.forename: Levent
authors.initials: L
authors.lastname: Sirvan
authors.forename: Salim
authors.initials: S
authors.lastname: Erkaya
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018394:CA-125 Antigen / Q000097:blood; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D059247:Fertility Preservation; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018394:CA-125 Antigen